BioCentury
ARTICLE | Targets & Mechanisms

CDK8 inhibitor: Senex's best thing

August 23, 2012 7:00 AM UTC

Chemotherapy is used to treat virtually every tumor type, but the drugs can blunt their own efficacy by inducing paracrine activity. Now, an international team led by Senex Biotechnology Inc. has mouse data showing that a cyclin dependent kinase 8 inhibitor can block the negative effects of at least one chemotherapeutic-doxorubicin.1

The unanswered questions include whether the cyclin dependent kinase 8 (CDK8) inhibitor enhances the efficacy of additional chemotherapies and targets cancer stem cells...